I totally agree. There is nothing to cheer about at this time. If SPPI can hold on to its gain, then there is something to look forward to but if its going to trade up and down and most of the time its down then
RAJ should go.
Another disappointing day from SPPI management with a fully diluted (.06) loss. The story of SPPI
Only the shorties and Raj and his management team who accumulating stock options are getting richer.
Retail investors are losing value on their investments.
I have been a long holder of SPPI and I have learned not to be overly optimistic about any good news coming from the company. It seems like this company has been cursed. Any goods news does not move this stock any higher but whenever there is a bad news, it dips like there is no bottom in sight. This is a disappointment
to say the least. It has many drugs in the pipeline but sales are underperforming.
Raj and his team are not putting money in R and D, they are putting it in their pockets. they buy companies that have the drugs already. the only thing is they market these drugs but they do not execute well in selling these drugs that is why SPPI is underperforming.
SPPI will be Up in a hurry if Raj and his management team are out of the way. They are the reason why SPPI is being shorted all the time.
There is nothing to cheer about on this stock. It goes up one day and get shorted the following day.
It never keep any gains it make. I think Raj and his management team are the reason for lack of confidence on this stock.
I have been holding on for so long on SPPI and it has been a disappointment. This stock will never go up until
Raj and his management goes. I think they are the reason this stock is being shorted all the time. Nobody
have confidence in this management team. They never deliver.
From her on out, ACAD will slowly grind its way up till NDA approval by the FDA. Just hoping that this will be
a commercial success unlike other drugs.
Sentiment: Strong Buy
Arna should seek a buy out bid from Eisai or other pharmaceuticals. This stock has gone bad since the FDA
approval of Belviq.
I think a lot of us are in the same boat. We have not heard anything from the company or the CEO
to address the current situation to stop the bleeding. There are a lot of other biotech companies that are
getting the drubbing and it is exacerbated by articles from SA and The Street especially from Adam F.
This is pathetic. There was a lot of hoopla prior to the FDA approval and ARNA skyrocketed from penny stock to a high of $12, now its coming back to a penny stock. The CEO should have just sold out to Eisai.
One analyst asked a lot of questions but not the most important thing which is when will the company turn the net income into positive territory?
Doesn't look good right now in AH trading which is down another .37. Hopefully with increase in revenue,
some analysts may upgrade.
I think CEO's should make a strong position and make a rebuttal on writers like Adam F. who is doing a dis-service to the bio-pharma who are doing scientific research to bring treatments for diseases that are currently
People were looking for an ICPT like pop on this stock today and all that we see is a horde of
people rushing to get out. I hope GALT management will make a statement to stem this selling
Why did FDA gave a fast track authorization on GR-MD-2 back in 2013 and have all of us rushed to buy
into GALT? Did we all get suckered into this drug? Can this drug still be salvage?
I remember IDIX about two years ago when their clinical trials for Hep C were a bust, and now a month ago
it is being purchased by Merck for $24. That is a turn around for IDIX which was left for dead.
Who is telling the truth, is Adam F. or GALT management? This is sickening for retail investors who are
depending on the management to be telling the truth that their clinical trials are on the verge of being
successful and could cure people with serious illness.
Every time some small bio tech stocks are moving up, Adam F. recycles his old articles to slam the upward moves of these bio techs. I think Adam F. is a cancer to small bio tech companies making sure that they
don't have a chance to move up higher no matter how noble their drugs are.